摘要
目的 探讨手术联合放疗及安罗替尼靶向药治疗非小细胞肺癌单发脑转移瘤患者临床疗效。方法 选择2019年1月—2022年1月该院肿瘤内科收治的77例非小细胞肺癌伴单发脑转移瘤患者作为治疗对象进行回顾性研究,根据不同的治疗方案分为对照组38例和观察组39例。对照组患者开展全脑放疗+立体定向放射治疗以及安罗替尼靶向药物治疗,观察组先进行手术切除单发脑转移瘤,然后给予放疗和安罗替尼靶向药物治疗;观察对照组和观察组患者脑转移瘤临床治疗效果,生活质量评分情况,7个月、1年以及2年生存率情况,不良反应发生率情况。结果观察组患者的脑转移瘤的临床治疗有效率82.05%及控制率89.74%均高于对照组39.47%及50.00%,差异有统计学意义(P<0.05);治疗后观察组生活质量评分高于对照组,差异有统计学意义(P <0.05);观察组经治疗后7个月、1年以及2年生存率(94.87%,74.36%,48.72%)明显高于对照组(68.42%,39.47%,23.68%),差异有统计学意义(P<0.05);观察组出现术后不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论 手术联合安罗替尼靶向药治疗非小细胞肺癌单发脑转移瘤患者,可有效提高单发脑转移瘤的临床治疗有效率,提高该类晚期癌症患者的部分生活质量以及生存率,并在一定程度上能够降低患者后续治疗的不良反应发生率。
Objective To investigate the clinical efficacy of surgery combined with radiotherapy and antirotinib in the treatment of non-small cell lung cancer patients with single brain metastases. Methods A total of seventy-seven patients with non-small cell lung cancer with single brain metastases admitted to the Department of Oncology of our hospital from January 2019 to January 2022 were selected as treatment objects for the treatment study.According to different treatment regiments, they were divided into control group(thirty-eight cases) and study group(thirty-nine cases).Control group received whole brain radiotherapy + stereotactic radiotherapy and antirotinib targeted drug therapy;study group received surgical resection of single brain metastases first, then radiotherapy and antirotinib targeted drug therapy;The clinical treatment effect, quality of life score, 7-month, 1-year and 2-year survival rate and incidence of adverse reactions of patients with brain metastases in the control group and the study group were observed. Results The clinical effective rate of brain metastases in the study group was 82.05% and the control rate was 89.74%,which were higher than those in the control group 39.47% and 50.00%,the difference was statistically significant(P<0.05).After treatment, the life quality score of the study group was higher than that of the control group, and the difference was statistically significant(P<0.05).The 7-month, 1-year and 2-year survival rates of the study group(94.87%,74.36%,48.72%) were significantly higher than those of the control group(68.42%,39.47%,23.68%),and the difference was statistically significant(P<0.05).The incidence of postoperative adverse reactions in the study group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Surgery combined with antirotinib targeting drugs in the treatment of patients with single brain metastases of non-small cell lung cancer can effectively improve the clinical effective rate of si
作者
郑国红
李娜
肖磊
李义慧
王晓红
ZHENG Guohong;LI Na;XIAO Lei;LI Yihui;WANG Xiaohong(Tangshan People's Hospital,Tangshan 063000,China)
出处
《中国煤炭工业医学杂志》
2023年第2期138-142,共5页
Chinese Journal of Coal Industry Medicine
基金
2019年河北省卫生健康委医学科学研究课题计划(编号:20190169)。
关键词
非小细胞肺癌单发脑转移瘤
放疗
安罗替尼
Single brain metastases in non-small cell lung cancer
Radiotherapy
Anlotinib
